Tevogen Bio Holdings Inc.
General ticker "TVGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $105.5M (TTM average)
Tevogen Bio Holdings Inc. does not follow the US Stock Market performance with the rate: -23.8%.
Estimated limits based on current volatility of 2.8%: low 6.14$, high 6.48$
Factors to consider:
- Total employees count: 3 as of 2021
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Inability to raise capital, Failure to obtain approval, Commercialization delays, Manufacturing disruptions, Regulatory and compliance
- Current price 10.4% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.11$, 29.29$]
- 2026-12-31 to 2027-12-31 estimated range: [3.84$, 16.10$]
Financial Metrics affecting the TVGN estimates:
- Negative: with PPE of -4.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -20.35 <= 0.30
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.11 > -0.65
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: -0.76 < Inventory ratio change, % of 0
- Negative: 0.01 < Interest expense per share per price, % of 0.32
Short-term TVGN quotes
Long-term TVGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.84MM | $53.56MM | $26.14MM |
| Operating Income | $-8.84MM | $-53.56MM | $-26.14MM |
| Non-Operating Income | $-51.63MM | $39.84MM | $-0.13MM |
| Interest Expense | $0.26MM | $0.18MM | $0.20MM |
| R&D Expense | $4.40MM | $31.03MM | $11.11MM |
| Income(Loss) | $-60.48MM | $-13.73MM | $-26.28MM |
| Net Income(Loss)* | $-60.48MM | $-13.73MM | $-26.28MM |
| Stockholders Equity | $-94.43MM | $-6.67MM | $-8.23MM |
| Assets | $5.51MM | $3.46MM | $4.38MM |
| Operating Cash Flow | $-8.17MM | $-12.00MM | $-12.33MM |
| Capital expenditure | $0.13MM | $0.00MM | $0.06MM |
| Investing Cash Flow | $-0.13MM | $0.00MM | $-0.06MM |
| Financing Cash Flow | $3.87MM | $12.23MM | $11.66MM |
| Earnings Per Share** | $-18.28 | $-4.68 | $-7.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.